ArticleInternational journal of clinical and experimental medicine2015
Fuzhisan, a chinese herbal medicine, suppresses beta-secretase gene transcription via upregulation of SIRT1 expression in N2a-APP695 cells.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Cooperative effects of SIRT1 and SIRT2 on APP acetylation.Aging cell · 2023Article
- The Multifaceted Role of Neuroprotective Plants in Alzheimer's Disease Treatment.Geriatrics (Basel, Switzerland) · 2022Review
- Nogo‑66 promotes β‑amyloid protein secretion via NgR/ROCK‑dependent BACE1 activation.Molecular medicine reports · 2021Article
- Article
- Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders.Neurochemical research · 2017Review
- Epigallocatechin Gallate Attenuates β-Amyloid Generation and Oxidative Stress Involvement of PPARγ in N2a/APP695 Cells.Neurochemical research · 2017Article
- Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus.Neurochemical research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accumulation of β-amyloid (Aβ) peptide plaques is the major pathogenic event in Alzheimer's disease (AD). Because β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) cleaves APP at the first amino acid of the Aβ domain and is the rate-limiting enzyme for Aβ peptide generation, the level of this aspartic protease is a focus of AD research. Fuzhisan (FZS), a Chinese herbal complex prescription that has been used for the treatment of AD for over 20 years, is known to enhance metabolic activity and cognitive ability in aged rats and AD patients. To confirm whether FZS's therapeutic effect related to BACE1 pathway, we investigated the intracellular molecules expression change after FZS treatment in N2a-APP695 cell line. In this study, we demonstrated that BACE1 transcription and translation were reduced, and SIRT1 expression was elevated in the N2a-APP695 cells treated with FZS. The therapeutic efficacy of FZS in AD may be derived from the downregulation of BACE1 expression.
Indexed as
Identifiers
26221262PMC4509207W1019650777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.